2003
DOI: 10.1136/gut.52.8.1211
|View full text |Cite
|
Sign up to set email alerts
|

Small bowel neoplasia in coeliac disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

7
58
3
6

Year Published

2005
2005
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 109 publications
(74 citation statements)
references
References 23 publications
7
58
3
6
Order By: Relevance
“…A further contribution to NF-κB activation also is determined by the upregulation of RAN protein (62) and of PRDX4 (63), and by the downregulation of PEBP1, also known as RKIP (64,65), all of which we found modulated in our series (Table 3). It is known that adult CD patients present a higher risk of developing cancer than the general population (4,5). In our series, we found the upregulation of known cancer-related proteins (RAN and PRDX4) (62,63) and the downregulation of PEBP1 (65).…”
Section: N T E S T I N a L M U C O S A T I S S U E P R O T E O M E supporting
confidence: 53%
See 1 more Smart Citation
“…A further contribution to NF-κB activation also is determined by the upregulation of RAN protein (62) and of PRDX4 (63), and by the downregulation of PEBP1, also known as RKIP (64,65), all of which we found modulated in our series (Table 3). It is known that adult CD patients present a higher risk of developing cancer than the general population (4,5). In our series, we found the upregulation of known cancer-related proteins (RAN and PRDX4) (62,63) and the downregulation of PEBP1 (65).…”
Section: N T E S T I N a L M U C O S A T I S S U E P R O T E O M E supporting
confidence: 53%
“…The prognosis of this subgroup of patients is poor, and they show a higher risk of developing an overt lymphoma and uncontrolled malabsorption. Moreover, overall CD patients present a higher risk of developing cancer (4,5). Cancers include T-and B-cell nonHodgkin lymphoma, oropharyngeal, esophageal and intestinal adenocarcinomas and pancreas tumors (6).…”
Section: Introductionmentioning
confidence: 99%
“…Although in the great majority of patients the prognosis of this disease is excellent, and most coeliac patients die for causes unrelated to CD, some of these patients may develop a series of serious complications, such as refractory CD type 1 and type 2 (RCD1 and RCD2), ulcerative jejunoileitis (UJI), enteropathyassociated T-cell lymphoma (EATL), abdominal B cell lymphoma (ABL), and small bowel carcinoma (SBC), which dramatically reduce ଝ This project was supported by a grant from the Fondazione Celiachia "Studio di possibili fattori ambientali e sviluppo di nuove strategie terapeutiche nelle complicanze della malattia celiaca". The funding source had no role.the prognosis [3][4][5][6][7]. In particular, the five-year survival rate is between 80% and 96% in patients with RCD1, between 40% and 58% in patients with RCD2 and drops to less than 20% in patients with CD complicated by EATL [8][9][10][11][12][13].…”
Section: Introductionmentioning
confidence: 99%
“…The first papers on the molecular diagnosis of complicated CD (CCD) were published more than 10 years ago [14], and since then several papers were published on this subject [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Despite these achievements, the literature still provides only minor and insufficient indications on the incidence of these conditions in patients with CD [8,[15][16][17][18][19].…”
Section: Introductionmentioning
confidence: 99%
“…In CD patients, exposure to gluten results in chronic inflammation of the small bowel mucosa characterized by intraepithelial lymphocytosis, crypt hyperplasia and villous atrophy (3,4). CD is a well-established risk factor for small bowel lymphoma (5)(6)(7). In several recent studies on CD patients, the association with small bowel adenocarcinomas (SBAs) was also investigated, and a relative risk of 10-to 80-fold for this tumor type was reported for CD (6,8,9).…”
Section: Introductionmentioning
confidence: 99%